The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive multiple sclerosis (PMS), but the New York biotech is pointing to other ...

Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...